Literature DB >> 11090155

Functional mapping of protective domains and epitopes in the rotavirus VP6 protein.

A H Choi1, M Basu, M M McNeal, J Flint, J L VanCott, J D Clements, R L Ward.   

Abstract

The purpose of this study was to determine which regions of the VP6 protein of the murine rotavirus strain EDIM are able to elicit protection against rotavirus shedding in the adult mouse model following intranasal (i.n.) immunization with fragments of VP6 and a subsequent oral EDIM challenge. In the initial experiment, the first (fragment AB), middle (BC), or last (CD) part of VP6 that was genetically fused to maltose-binding protein (MBP) and expressed in Escherichia coli was examined. Mice (BALB/c) immunized with two 9-microg doses of each of the chimeras and 10 microg of the mucosal adjuvant LT(R192G) were found to be protected against EDIM shedding (80, 92, and nearly 100% reduction, respectively; P </= 0.01) following challenge. Because CD produced almost complete protection, we prepared four E. coli-expressed, MBP-fused chimeras containing overlapping fragments of the CD region (i.e., CD1, CD2, CD3, and CD4) whose lengths ranged from 61 to 67 amino acid residues. Following i.n. immunization, CD1, CD2, and CD4 induced significant (P </= 0.004) protection (88, 84, and 92% reduction, respectively). In addition, 11 peptides (18 to 30 residues) of the CD region with between 0 and 13 overlapping amino acids were synthesized. Two 50-microg doses of each peptide with LT(R192G) were administered i.n. to BALB/c mice. Five peptides were found to elicit significant (P </= 0.02) protection. Moreover, a 14-amino-acid region within peptide 6 containing a putative CD4(+) T-cell epitope was found to confer nearly complete protection, suggesting a protective role for CD4(+) T cells. Mice that were protected by fragments BC and CD1 and four of the five protective synthetic peptides did not develop measurable rotavirus antibodies in serum or stool, implying that protection induced by these domains was not dependent on antibody. Together, these observations suggest that multiple regions of VP6 can stimulate protection, a region of VP6 as small as 14 amino acids containing a CD4(+) T-cell epitope can stimulate nearly complete protection, and protection mediated by a subset of epitopes in the VP6 protein does not require antibodies in BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090155      PMCID: PMC112438          DOI: 10.1128/jvi.74.24.11574-11580.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru.

Authors:  C F Lanata; K Midthun; R E Black; B Butron; A Huapaya; M E Penny; G Ventura; A Gil; M Jett-Goheen; B L Davidson
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 2.  Chemistry of peptides associated with MHC class I and class II molecules.

Authors:  H G Rammensee
Journal:  Curr Opin Immunol       Date:  1995-02       Impact factor: 7.486

Review 3.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

5.  Identification of a T-helper cell epitope on the rotavirus VP6 protein.

Authors:  D M Baños; S Lopez; C F Arias; F R Esquivel
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 6.  The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.

Authors:  H F Clark; P A Offit; R W Ellis; J J Eiden; D Krah; A R Shaw; M Pichichero; J J Treanor; F E Borian; L M Bell; S A Plotkin
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

7.  Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil.

Authors:  A C Linhares; Y B Gabbay; J D Mascarenhas; R B de Freitas; C S Oliveira; N Bellesi; T A Monteiro; Z Lins-Lainson; F L Ramos; S A Valente
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

8.  Alternate binding of actin and calmodulin to multiple sites on dystrophin.

Authors:  H W Jarrett; J L Foster
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

9.  Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.

Authors:  M B Rennels; R I Glass; P H Dennehy; D I Bernstein; M E Pichichero; E T Zito; M E Mack; B L Davidson; A Z Kapikian
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

10.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more
  22 in total

1.  Norovirus P particle, a novel platform for vaccine development and antibody production.

Authors:  Ming Tan; Pengwei Huang; Ming Xia; Ping-An Fang; Weiming Zhong; Monica McNeal; Chao Wei; Wen Jiang; Xi Jiang
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

2.  Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection.

Authors:  Jonathan R Kurtz; Hailey E Petersen; Daniel R Frederick; Lisa A Morici; James B McLachlan
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

4.  Cloning and nucleotide sequence analyses of 11 genome segments of two American and one British equine rotavirus strains.

Authors:  Yongping Ma; Xiaobo Wen; Yasutaka Hoshino; L Yuan
Journal:  Vet Microbiol       Date:  2015-01-15       Impact factor: 3.293

5.  Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.

Authors:  Ming Xia; Pengwei Huang; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2019-06-11       Impact factor: 3.641

6.  Characterization of homologous and heterologous rotavirus-specific T-cell responses in infant and adult mice.

Authors:  María C Jaimes; Ningguo Feng; Harry B Greenberg
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Comprehensive analysis of contributions from protein conformational stability and major histocompatibility complex class II-peptide binding affinity to CD4+ epitope immunogenicity in HIV-1 envelope glycoprotein.

Authors:  Tingfeng Li; N Kalaya Steede; Hong-Nam P Nguyen; Lucy C Freytag; James B McLachlan; Ramgopal R Mettu; James E Robinson; Samuel J Landry
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

8.  Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.

Authors:  Davide Agnello; Christine A Hervé; Amandine Lavaux; Magali Darniot; Patrice Guillon; Annie Charpilienne; Pierre Pothier
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

10.  Non-structural protein NSP2 induces heterotypic antibody responses during primary rotavirus infection and reinfection in children.

Authors:  Carl D Kirkwood; Karen Boniface; Simone Richardson; Zenobia F Taraporewala; John T Patton; Ruth F Bishop
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.